CANY
ENTA icon

Caxton Associates (New York)’s Enanta Pharmaceuticals ENTA Stock Holding History

Caxton Associates (New York)’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,028
Closed -$201K – 485
2023
Q3 		$201K Buy
+18,028
New +$290K 0.03% 359
2022
Q3 		– Sell
-13,843
Closed -$654K – 523
2022
Q2 		$654K Buy
+13,843
New +$751K 0.06% 209
2018
Q4 		– Sell
-2,815
Closed -$241K – 338
2018
Q3 		$241K Sell
2,815
-496
-15% -$49.7K 0.02% 354
2018
Q2 		$384K Hold
3,311
– – 0.02% 280
2018
Q1 		$268K Buy
+3,311
New +$255K 0.01% 299

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caxton Associates (New York)'s ENTA Position: Q4 2023 in Review

Caxton Associates (New York) sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 18,028 shares — an estimated $201K sold.

Caxton Associates (New York) first reported a position in ENTA in Q1 2018 and held it in 5 quarters. The position peaked at $654K in Q2 2022. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Caxton Associates (New York) reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 18,028 Enanta Pharmaceuticals shares in Q4 2023, an estimated $201K.
  • Caxton Associates (New York) first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Caxton Associates (New York)'s Enanta Pharmaceuticals position peaked at $654K in Q2 2022.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Caxton Associates (New York)'s 13F filing for Q4 2023, filed 14 Feb 2024.